{"id":"NCT04435366","sponsor":"IVERIC bio, Inc.","briefTitle":"A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)","officialTitle":"A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-06-22","primaryCompletion":"2022-07-25","completion":"2023-08-22","firstPosted":"2020-06-17","resultsPosted":"2023-12-28","lastUpdate":"2024-12-12"},"enrollment":448,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Geographic Atrophy","Macular Degeneration"],"interventions":[{"type":"DRUG","name":"Avacincaptad Pegol","otherNames":["Zimura (previous name)","IZERVAY"]},{"type":"DRUG","name":"Sham","otherNames":[]}],"arms":[{"label":"Avacincaptad Pegol","type":"EXPERIMENTAL"},{"label":"Sham","type":"SHAM_COMPARATOR"},{"label":"Avacincaptad pegol and Sham","type":"EXPERIMENTAL"}],"summary":"The objectives of this study was to evaluate the safety and efficacy of avacincaptad pegol intravitreal administration in participants with geographic atrophy secondary to age-related macular degeneration (AMD)","primaryOutcome":{"measure":"The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by Autofluorescence (FAF) at 3 Time Points: Baseline, Month 6, and Month 12","timeFrame":"Baseline to month 12","effectByArm":[{"arm":"Avacincaptad Pegol","deltaMin":0.336,"sd":0.032},{"arm":"Sham","deltaMin":0.392,"sd":0.033}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0064"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":6},"locations":{"siteCount":205,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Colombia","Croatia","Czechia","Estonia","France","Germany","Hungary","Israel","Italy","Latvia","Poland","Spain","United Kingdom"]},"refs":{"pmids":["37696275","37314061"],"seeAlso":["https://www.clinicaltrials.astellas.com/study/ISEE2008/","https://www.trialsummaries.com/Study/StudyDetails?id=26044&tenant=MT_AST_9011"]},"adverseEventsSummary":{"seriousAny":{"events":31,"n":225},"commonTop":["Conjunctival haemorrhage","Choroidal neovascularisation","COVID-19","Fall","Urinary tract infection"]}}